Short Interest in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Expands By 69,900.0%

Key Points

• Short interest in Ventyx Biosciences surged by 69,900.0% in July, reaching a total of 4,970,000 shares, compared to just 7,100 shares at the end of June.
• The company's stock fell by 4.8%, trading at $2.67, with a short-interest ratio of 3.0 days and approximately 7.9% of its stock sold short.
• Ventyx recently reported earnings of ($0.39) EPS, beating estimates and currently has a projected EPS of ($2.09) for the fiscal year.

Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) was the target of a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 4,970,000 shares, anincreaseof69,900.0% from the June 30th total of 7,100 shares. Based on an average daily trading volume, of 1,630,000 shares, the short-interest ratio is currently 3.0 days. Approximately7.9% of the company's shares are short sold. Approximately7.9% of the company's shares are short sold. Based on an average daily trading volume, of 1,630,000 shares, the short-interest ratio is currently 3.0 days.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Y Intercept Hong Kong Ltd purchased a new stake in Ventyx Biosciences during the second quarter worth about $148,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of Ventyx Biosciences in the second quarter valued at approximately $71,000. CWM LLC raised its position in shares of Ventyx Biosciences by 7.6% in the second quarter. CWM LLC now owns 57,145 shares of the company's stock valued at $122,000 after buying an additional 4,057 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its position in shares of Ventyx Biosciences by 104.1% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 46,711 shares of the company's stock valued at $100,000 after buying an additional 23,828 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in Ventyx Biosciences by 21.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 29,657 shares of the company's stock valued at $62,000 after purchasing an additional 5,174 shares during the period. 97.88% of the stock is owned by hedge funds and other institutional investors.

Ventyx Biosciences Stock Down 0.2%

Ventyx Biosciences stock traded down $0.01 during mid-day trading on Tuesday, reaching $2.72. 123,518 shares of the company's stock were exchanged, compared to its average volume of 1,421,708. The company has a market cap of $193.20 million, a P/E ratio of -1.55 and a beta of 0.97. Ventyx Biosciences has a twelve month low of $0.78 and a twelve month high of $3.39. The company has a fifty day moving average of $2.46 and a 200-day moving average of $1.80.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.09. Equities research analysts expect that Ventyx Biosciences will post -2.09 earnings per share for the current fiscal year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.